• 1
    Levine P, Katzin EM, Burnham L: Isoimmunization in pregnancy: its possible bearing on the etiology of erythroblastosis fetalis. JAMA 1941; 116:825827
  • 2
    Chown B: Anaemia from bleeding of the fetus into the mother’s circulation. Lancet 1954; 266:12131215
  • 3
    Avent ND, Reid ME: The Rh blood group system: a review. Blood 2000; 95:375387
  • 4
    Pollack W, Gorman JG, Freda VJ, et al. : Results of clinical trials of RhoGAM in women. Transfusion 1968; 8:151153
  • 5
    Urbaniak SJ, Greiss MA: RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000; 14:4461
  • 6
    Chilcott J, Lloyd Jones M, Wight J, et al. : A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 2003; 7:iii62
  • 7
    EU Committee of Ministers: Recommendation N° R(90) 9 of the Committee of Ministers to Member States on Plasma Products and European Self-Sufficiency. Brussels, European Union, 1990
  • 8
    World Health Organisation: Towards 100% Voluntary Blood Donation. A Global Framework for Action. Geneva, WHO, 2010
  • 9
    Beliard R: Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials. Transfus Clin Biol 2006; 13:5864
  • 10
    Miescher S, Spycher MO, Amstutz H, et al. : A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. Blood 2004; 103:40284035
  • 11
    Olovnikova NI, Belkina EV, Berkovskii AL, et al. : [Monoclonal anti-D immunoglobulin for prevention of hemolytic disease of the newborn]. Gematol Transfuziol 1994; 39:36
  • 12
    Kumpel BM: In vivo studies of monoclonal anti-D and the mechanism of immune suppression. Transfus Clin Biol 2002; 9:914
  • 13
    Olovnikova NI, Ershler MA, Belkina EV, et al. : Effect of producer cell line on functional activity of anti-D monoclonal antibodies destined for prevention of rhesus sensitization. Bull Exp Biol Med 2009; 147:448452
  • 14
    Kumpel BM: Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007; 93:99111
  • 15
    Abès R, Teillaud JL: Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 2010; 3:146157
  • 16
    De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. : Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140:635643
  • 17
    Beliard R, Waegemans T, Notelet D, et al. : A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141:109119
  • 18
    Siberil S, de Romeuf C, Bihoreau N, et al. : Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions. Clin Immunol 2006; 118:170179
  • 19
    Mollison PL, Hughes-Jones NC: Clearance of Rh-positive red cells by low concentrations of Rh antibody. Immunology 1967; 12:6373
  • 20
    Scott M: Section 1A: Rh serology. Coordinator’s report. Transfus Clin Biol 2002; 9:2329
  • 21
    Thorpe SJ, Fox B, Turner C, et al. : Competitive enzyme-linked immunoassay of monoclonal immunoglobulin G anti-D preparations. Transfus Med 2003; 13:153159
  • 22
    Frandsen TP, Naested H, Rasmussen SK, et al. : Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol Bioeng 2011; 108:21712181
  • 23
    Committee for Medicinal Products for Human Use: Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. London, EMA, 2007
  • 24
    Mire-Sluis AR, Barrett YC, Devanarayan V, et al. : Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289:116
  • 25
    EMEA/CHMP: Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. London, EMEA/CHMP, 2007
  • 26
    Miller KJ, Bowsher RR, Celniker A, et al. : Workshop on bioanalytical methods validation for macromolecules: summary report. Pharm Res 2001; 18:13731383
  • 27
    Food and Drugs Administration: Guidance for Industry, Bioanalytical Method Validation. Rockville, USA, U.S. Department of Health and Human Services, 2001
  • 28
    Suntharalingam G, Perry MR, Ward S, et al. : Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:10181028
  • 29
    Jilma-Stohlawetz P, Reiter RA, Panzer S, et al. : Pharmacokinetics (PK) of S/D treated anti-D immunoglobulin after intramuscular injection in healthy volunteers: gender differences in PK. Transfus Apher Sci 2005; 33:135140
  • 30
    Bichler J, Schondorfer G, Pabst G, et al. : Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG 2003; 110:3945
  • 31
    Bichler J, Spycher MO, Amstutz HP, et al. : Pharmacokinetics and safety of recombinant anti-RhD in healthy RhD-negative male volunteers. Transfus Med 2004; 14:165171